FATE Q4 2019 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+68.7% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$29M-1037.8% margin

Net Income

-$28M-1010.1% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

+15.4%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$28M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$302M

Total Liabilities

$58M

Stockholders' Equity

$245M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+68.7%
Gross Profit	$3M	-$12M	+122.5%
Operating Income	-$29M	-$17M	-73.7%
Net Income	-$28M	-$16M	-76.6%